Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 299 |
| INN | Potravitug |
| Status | Clinical |
| Drug code(s) | AntiBKV, MTX-005, mAb129 |
| Brand name | None |
| mAb sequence source | mAb human |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | TBD |
| Light chain isotype | TBD |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | BK virus |
| Indications of clinical studies | BK virus infection |
| Primary therapeutic area | Infectious diseases |
| Most advanced stage of development (global) | Phase 2/3 |
| Status | Active |
| Start of clinical phase (IND filing or first Phase 1) | May 15, 2022 |
| Start of Phase 2 | |
| Start of Phase 3 | April 10, 2023 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Memo Therapeutics AG |
| Licensee/Partner | None |
| Comments about company or candidate | May 2023: Fast track designation granted by FDA NCT05769582 Phase 2/3 study BKV Infection in Kidney Transplant Recipients is started in April 2023. May 31, 2022 – Memo Therapeutics AG announced today the initiation of a phase 1 clinical study targeting BK polyomavirus (“BKV”) infection in renal transplant patients. The phase 1, single-blind, partially randomized, placebo-controlled study will assess safety, tolerability, and pharmacokinetics of single and multiple ascending intravenous doses of MTX-005 in up to 56 healthy adult volunteers (ClinicalTrials.gov Identifier: NCT05358106). NCT05358106 Phase 1 started in May 2022; BLA expected in 2024. |
| Full address of company | Wagistrasse 27 8952 Schlieren / Zurich Switzerland Europe Switzerland https://memo-therapeutics.com/contact.html |
AntiBKV is a fully human highly neutralising antibody against BKV; derived from clinically selected convalescent BKV patients
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |